◼ Archived
Business
Novo explores macrocycles’ potential in $1.4B cardiometabolic pact with Danish biotech
Novo Nordisk signs a licensing agreement worth up to $1.4 billion with Orbis Medicines to develop oral therapeutics.
Cardiometabolic Diseases
1 trends tracked about this subject — the full history, oldest to newest below.